Semaglutide for Childhood Obesity

(GLOW Trial)

This trial tests the medication semaglutide to determine its effectiveness in helping teens manage obesity. Researchers are examining whether varying levels of health behavior and lifestyle treatments (HBLT), such as group classes and goal-setting sessions, should accompany the medication. The study aims to identify whether a high, medium, or low dose of these lifestyle treatments is most effective. Teens aged 12 to 17 with a BMI in the 95th percentile or higher, who can participate in virtual sessions, may be suitable candidates for this trial. As a Phase 4 trial, this research seeks to understand how an already FDA-approved and effective treatment can benefit more patients.

Research has shown that semaglutide is generally safe for people. The FDA has approved semaglutide for treating type 2 diabetes and obesity in adults, indicating a well-understood safety profile. In studies with adults, most participants tolerated semaglutide well. Common side effects included mild symptoms like nausea and diarrhea. Serious side effects were rare, but monitoring for them remains important. Since this study is in a later phase, semaglutide has demonstrated considerable safety up to this point.¹²³⁴⁵

Researchers are excited about semaglutide for treating childhood obesity because it offers a new approach compared to standard treatments like lifestyle changes, diet, and exercise alone. Semaglutide is unique because it mimics a hormone called GLP-1 that helps regulate appetite and insulin levels, potentially leading to more effective weight management in children. Unlike other treatments that primarily focus on behavior modification, semaglutide directly influences the body’s biological processes to help reduce hunger and control weight. This could make it a promising option for children struggling with obesity who need more than traditional methods to achieve and maintain a healthy weight.

Research has shown that semaglutide effectively helps teenagers lose weight. In one study, participants taking semaglutide lost an average of 9.7 kg (about 21 pounds) over a year, equating to about 8.9% of their total body weight. Another study found that nearly 37% of teens using semaglutide lost more than 20% of their weight, with an average loss of about 15 kg. Additionally, teens on semaglutide saw their BMI (body mass index) drop by an average of 16.1% during the study. These results suggest that semaglutide can significantly aid teens with obesity in losing weight.